Corporate Update: Pluri Inc. (PLUR) Shares Decline
Pluri Inc. (ticker: PLUR) experienced a 3.81 % decline in its share price during the 24‑hour trading window concluding at 02:40 AM Central European Time on Saturday, 24 November 2026. The stock is currently trading at approximately USD 0.99 on major exchanges. With an outstanding supply of 10.8 million shares, the company’s market capitalization stands at USD 13 million. In the last 24 hours, total trading volume amounted to roughly USD 9,700.
Recent Performance
- Month‑to‑date: Since the close of the previous month, PLUR has declined by 4.72 %.
- 200‑Day Moving Average: USD 2.44.
- 52‑Week Range: The highest price achieved was USD 4.87 on 13 November 2025, while the lowest was USD 0.85 on 19 October 2026.
Peer Activity (Last 24 Hours)
| Company | Symbol | Movement | Current Price | Market Cap | Notable Ratio |
|---|---|---|---|---|---|
| Sisram Medical | 1696.HK | Down 6.22 % | HKD 1.81 | HKD 110.9 M | P/E 9.66 |
| Regentis Biomaterials/Is | RGNT | Up 1.36 % | USD 1.28 | USD 9.8 M | – |
| Chemomab Therapeutics | CMMB | Down 2.54 % | USD 1.03 | USD 8.4 M | – |
| Rocketdna | RKT.AX | Flat 0 % | AUD 0.02 | AUD 20.8 M | – |
| Collplant Biotechnologies Ltd | CLGN | Down 3.22 % | USD 3.67 | USD 8.5 M | – |
Company Focus
Pluri Inc. specializes in mesenchymal stem cell (MSC) production technology, translating scientific breakthroughs into commercial cell‑therapy products. The firm targets a broad spectrum of disorders—including severe hematologic diseases, cardiovascular conditions, autoimmune disorders, and other critical health challenges—through its global customer base. Further details about their product pipeline and clinical milestones can be accessed via the company’s website at www.pluri‑biotech.com . Pluri is listed on the Nasdaq exchange.
Outlook
While the recent dip in share price reflects short‑term market volatility, Pluri’s underlying technology platform remains positioned to capture significant therapeutic value. Continued progress in clinical development and strategic partnerships will likely dictate the company’s trajectory in the coming quarters. Investors and market participants should monitor upcoming clinical data releases and regulatory approvals, which could materially influence PLUR’s valuation trajectory.
